Market
Story
FDA Approves Eli Lilly's Zepbound (tirzepatide) as First and Only Treatment for Obstructive Sleep Apnea in Adults with Obesity
Dec 20, 2024, 09:34 PM
The U.S. Food and Drug Administration (FDA) has approved Eli Lilly's Zepbound® (tirzepatide) for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. This approval marks Zepbound as the first and only prescription medication specifically indicated for this condition in this patient population. The approval was confirmed by multiple sources, highlighting its significance in addressing sleep apnea associated with obesity.
View original story
Similar markets
More than 60 • 25%
Less than 20 • 25%
20 to 40 • 25%
40 to 60 • 25%
Other • 25%
European Union • 25%
United Kingdom • 25%
Australia • 25%
500,000 to 1 million • 25%
1 million to 2 million • 25%
More than 2 million • 25%
Less than 500,000 • 25%
Other • 25%
European Medicines Agency (EMA) • 25%
Medicines and Healthcare products Regulatory Agency (MHRA) • 25%
Therapeutic Goods Administration (TGA) • 25%
Less than 100,000 • 25%
100,000 to 200,000 • 25%
200,000 to 300,000 • 25%
More than 300,000 • 25%
5 or more new partnerships • 25%
0 new partnerships • 25%
1-2 new partnerships • 25%
3-4 new partnerships • 25%
51% to 60% • 25%
More than 60% • 25%
Less than 40% • 25%
40% to 50% • 25%